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Abstract
Despite all the available therapies, Acute Lymphoblastic Leukemia (ALL) remains extremely difficult to eradicate. Current available 
therapies, which include chemotherapy, radiation, and stem cell transplants, tend to be more successful in treating children than 
adults . While adults are more likely than children to relapse after treatment, the most common cause of treatment failure in 
children is also relapse. Improved outcomes for all ALL patients may depend upon new immunotherapies, specifically CAR T-cell 
therapy. CAR T-cell therapy extracts a patient’s own T-cells and modifies them with a CD19 antigen. This modification allows the 
new T-cells to recognize and kill cancer cells that contain the antigen on their surfaces, like leukemia cells do . Although CAR T-cell 
therapy may cause toxicities such as Cytokine Release Syndrome (CRS), they are mostly short term and reversible . Trials indicate 
that almost all patients who undergo CAR T-cell therapy will enter complete remission . Though a large percentage of those patients 
will experience a relapse, relapse rates of CAR T-cell therapy are lower than other treatments . By reviewing the available research 
literature regarding CAR T-cell therapy, this paper examines the effectiveness of this therapy in different patient populations and 
demonstrates that CAR T-cell therapy significantly improves event-free survival rates in ALL patients.
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Introduction
The leading cause of disease related death in U.S. pediatric pa-
tients is cancer, most commonly Acute Lymphoblastic Leukemia 
(ALL) (Tumaini, et. al., 2013). For many years, cancer treatments 
were limited to radiation therapy, chemotherapy, or surgery. More 
recently, newer types of treatments called immunotherapies, have 
become available. Cancer immunotherapies are therapies that 
enlist and strengthen the power of a patient’s immune system to 
fight and attack the cancer. Of the immunotherapies discovered, 
adoptive cell transfer (ACT), in which a patient’s own immune 
cells are collected and used to treat their cancer, has achieved 
the most successful outcomes. The most effective ACT therapy 
is CAR T-cell therapy (Brentjens, et. al., 2013). In 2017, CAR T-cell 
therapy was approved by the FDA as a treatment for ALL and for 
adults with advanced forms of lymphoma. However, while it may 
seem that CAR T-cell therapy is poised to revolutionize cancer 
therapy, some of the optimism surrounding it is tempered by con-
cerns about its safety and potentially severe toxicities (Lim, June, 
2017), calling into question if CAR T-cell therapy is an improved 
treatment for ALL and relapsed ALL.
Methods
The research used in this paper was located and compiled 
from papers obtained through Touro College’s access to on-
line publications. Google Scholar and Blood Journal were used 
for additional references. The articles were critically selected, 
compared, and analyzed to evaluate if CAR T-cell therapy is an 
effective treatment for ALL.
CAR T-cell Therapy
CAR T-cell therapy is relatively straight forward. T-cells, which 
play a critical role in orchestrating an immune response, are re-
sponsible for killing cells that are infected by pathogens. In order 
to retrieve these T-cells, blood is drawn from a patient and the 
T-cells are separated from the rest of the blood. The T-cells then 
undergo genetic modification via the insertion of genes that 
encode for tumor specific chimeric antigen receptors (CARs). 
These receptors allow the T-cells to recognize and subsequently 
attach to a specific antigen. The antigen CD19 was chosen be-
cause it is universally expressed on all ALL tumor cells and not 
on pluripotent hematopoietic stem cells (Tumaini, et. al., 2013). 
Once the T-cells have been successfully engineered to express 
the CD19 antigen, they are expanded in a lab to form hundreds 
of millions of cells. This process has been refined and advanced 
over the years and can now quickly create large quantities of 
T-cells that have genetically engineered receptors on their sur-
face to treat both pediatric and adult ALL patients. The CAR 
T-cells are then infused back into the patient’s body where they 
continue to multiply, recognize, and kill the cancer cells con-
taining the antigen on their surfaces (Tumaini, et. al., 2013). This 
step is considered to be an in vivo expansion, which requires 
the new host to support these engineered T-cells. Therefore, the 
administration of the T-cells is preceded by a lymphodepleting 
regimen, as lymphopenia (the condition of having an abnormally 
low level of lymphocytes in the blood) generates changes that 
support T-cell expansion and survival (Klebanoff, et. al., 2005). As 
a result, most adoptive cell therapy protocols incorporate some 
version of lymphotoxic therapies prior to cell transfer.
Like most cancer treatments, CAR T-cell therapy has serious 
side effects. The most common side effect that patients usually 
experience is cytokine release syndrome (CRS). Notably, CRS 
has been seen in patients treated with other immunotherapies 
and is therefore not limited to CAR T-cell therapy (Lee, et. 
al., 2014; Teachey et al., 2013). CRS is caused by the cytokines 
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released from the T-cells as CAR T-cells rapidly expand within 
the patient’s body. It can also be caused by other immune cells, 
such as macrophages that might produce cytokines in response 
to the cytokines produced by the infused CAR T cells. CRS 
patients have high levels of IL-6 (the cytokine secreted by the 
T-cells) and is characterized by systemic symptoms that usually 
begin with a fever (Giavridis, et. al., 2018). The onset of the fever 
can range from a few hours after the treatment to more than 
a week after CAR T-cell infusion (Brudno, Kochenderfer, 2016). 
The fever is followed by nausea, chills, headaches, muscle pain, 
and difficulty breathing (Maude et al., 2014).
CRS can lead to many different related toxicities that attack 
organ systems. Cardiovascular toxicities most commonly cause 
tachycardia, although more severe cases of CRS have prompted 
hypotension, arrhythmia (irregular heartbeat), and decreased 
cardiac ejection fraction. CRS can lead to pulmonary edema 
and hypoxia, the deficiency in the amount of oxygen reaching 
the tissues that may require mechanical ventilation. It can also 
lead to reduced renal perfusion, the volume of blood delivered 
to the kidneys per unit time, which can cause a kidney injury. 
However, CAR T-cell related renal injuries are mostly reversible. 
The same goes for other laboratory abnormalities that CRS 
causes, such as elevated levels of bilirubin and/or serum trans-
aminases. Patients also commonly become neutropenic and 
lymphogenic when undergoing and following CAR T-cell therapy 
because they are severely immunocompromised and are not 
protected against opportunistic infections, such as salmonella, 
bacteremia, and urinary tract infections. Viral infections such as 
influenza, respiratory syncytial virus, and herpes zoster virus, 
have also been known to affect patients following CAR T-cell 
infusion (Brudno, Kochenderfer, 2016). Unfortunately, in such a 
setting, fevers, tachycardia, hypotension, and other regular symp-
toms associated with CRS can be difficult to differentiate from 
sepsis, which is a life-threatening infection. In an early trial, a 
patient with chronic lymphocytic leukemia who received che-
motherapy prior to his CAR T-cell treatment died with fever, 
hypotension, and renal failure four days after the administration 
of the CAR T-cells. It was discovered later that there were ele-
vated serum levels of inflammatory cytokines before CAR T-cell 
infusion, suggesting that the patient had a prior infection that 
caused his death (Brentijens, Curran, 2012).  
CAR T-cell therapy also has neurological toxicities associated 
with the treatment. The toxicities can be diverse, as they do 
not always localize to one specific area of the nervous system. 
The occurrence of neurologic toxicity is quite variable, with 
published reports stating that there is a 0% to 50% chance of 
neurological toxicities developing (Brudno, Kochenderfer, 2016). 
Neurologic events are not always associated with CRS toxici-
ties, which suggests that in some cases, they might have a differ-
ent mechanism than many of the other usual toxicities caused 
by CRS, such as fever and hypotension (Maude, et. al., 2014). 
Ironically, CRS is considered to be an “on-target” effect of 
CAR T-cell therapy, as the presence of the cytokines show that 
the T-cells are working in the body. Various grading systems for 
the “CRS-related adverse events” caused by immunotherapies 
have been proposed. They depend on many things, such as the 
temperature of the fever, the number of severe signs of toxici-
ties, and cytokine levels in the patient.  A category of severe CRS 
is defined as CRS requiring pharmacologic and medical inter-
vention. In such cases, tocilizumab, an IL-6 receptor antagonist 
that is used to treat rheumatologic disorders, is used as a first 
line agent. While not approved for this use by the FDA, it has 
effectively treated CRS-related toxicities in clinical trials with no 
life threatening or toxic effects (Maude, et. al., 2014), and is now 
a widely used off-label for the patients who have received CAR 
T-cell infusions. (Brudno, Kochenderfer, 2016).
Systemic corticosteroids have also been used for CRS-related 
toxicities. However, there is some evidence that corticosteroids 
can possibly inhibit CAR T-cell persistence and anti-malignancy 
efficacy. For this reason, corticosteroid therapy is only used as a 
last resort if the tocilizumab does not succeed in ameliorating 
the CRS. However, because neurologic toxicities may not come 
along with CRS, these toxicities may differ from that of CRS 
alone. It is unclear if tocilizumab has any beneficial effect on neu-
rologic toxicities, as severe neurologic toxicities are commonly 
treated with systemic corticosteroids right away, rather than 
initially beginning with tocilizumab.
Toxicities caused by CAR T-cells are diverse. Management 
of these toxicities requires continuous and vigilant monitoring, 
aggressive supportive treatments, and, in some cases, intensive 
care. Another harmful side effect of CAR T-cell therapy is that 
the engineered CAR T-cells with the CD-19 receptor could dam-
age other tissues that express the antigen recognized by it. This 
mechanism of toxicity can be mostly eliminated by searching for 
any expression of the targeted antigen on normal tissues in the 
body prior to the development of the CAR (Lamers, et. al., 2013).
Other Therapies
There are several other therapies used to treat ALL. The goal 
of these treatments is to remove all traces of the ALL from the 
patient. The most commonly used treatment for ALL is chemo-
therapy. The chemo treatment is divided into three phases. The 
first stage is known as the induction phase and usually takes 
about a month. The next phase, consolidation, also referred to 
as intensification, is, as its name suggests, extremely intense as 
well, and typically lasts for a few months. The last phase, mainte-
nance, or post-consolidation, is less intensive, and lasts for about 
two years (Pui, et. al., 2008).
The goal of induction, is to remove more than 99% of the 
initial leukemia cells from the patient and to restore normal 
haemopoiesis, the production of blood cells and platelets in the 
bone marrow. Afterwards, if both the blood and bone marrow 
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show no evidence of persistent leukemia and blood counts have 
returned to normal, then the patient achieves remission. Studies 
show that 96 to 99% of children with ALL enter remission after 
the induction treatment. Adults have a lower remission rate with 
only 78-93% of adults entering clinical remission (Pui, et. al., 2008). 
Nevertheless, a remission is not necessarily a cure, and since the 
first month is such intense treatment, many complications and 
serious infections can arise. As a result, this phase of treatment 
requires lengthy hospital stays and frequent visits to the doctor, 
as these complications can be life-threatening. Recent advances in 
supportive care have helped lower these complication rates, mak-
ing them considerably less common than they have previously 
been. Examples of supportive care are better nursing care, prop-
er nutrition, prescribed antibiotics, and red blood cell or platelet 
transfusions as needed (Locatelli, et. al., 2012).
There are three major types of drugs that children with stan-
dard-risk ALL receive during the first month of treatment. These 
are chemotherapy drugs L-asparaginase and vincristine, as well 
as a steroid drug, usually dexamethasone (Goekbuget, et al., 
2005). For children in high-risk groups, a fourth drug from the 
anthracycline class, typically daunorubicin, is added. ALL patients 
also require chemotherapy via the cerebrospinal fluid (CSF), as 
there may be leukemia cells that spread to the brain and spinal 
cord. This treatment is known as intrathecal chemotherapy and 
given through a lumbar puncture/spinal tap. Patients with high 
risk leukemia or leukemia in their CSF receive this treatment 
more frequently than other ALL patients do. In the past, along 
with intrathecal therapy, patients were also given prophylactic 
cranial irradiation. Recent studies have found that children who 
are given more intensive chemotherapy may not need radia-
tion therapy at all. Doctors try to avoid giving radiation to the 
brain, especially in younger children, because even low doses 
may result in problems with cognition, growth, and development 
(Locatelli, et al., 2012). 
The next phase, consolidation, is the phase of chemotherapy 
that further reduces the number of leukemia cells still in the body. 
Several chemo drugs are used together to prevent the remaining 
leukemia cells from developing a resistance. Intrathecal therapy is 
continued at this time, and patients with high-risk leukemia usual-
ly receive more intense chemotherapy. During this phase, patients 
with Philadelphia chromosome-positive ALL may benefit from the 
addition of other types of cancer therapies, such as targeted can-
cer drugs or stem cell transplants (Pui, et. al., 2008). 
If the leukemia remains in remission after induction and 
consolidation, the third phase, maintenance therapy, can begin. 
Most treatments use medication given either as pills or intra-
venously, and a steroid, usually prednisone or dexamethasone. 
Depending on the type of ALL and the risk of recurrence, other 
drugs may be added as needed. In the beginning of the mainte-
nance phase, most treatment plans include one or two repeat 
intensified treatments like the initial induction. These four-week 
intensifications are called re-induction or delayed intensification. 
Some children at higher risk may receive more intense mainte-
nance chemotherapy and intrathecal therapy. The total length 
for the three phases of chemotherapy for most ALL treatment 
plans is two to three years. However, patients with a higher risk 
of relapse are given several extra months of treatment as an 
added precaution (Pui, et. al., 2008). 
Throughout the entire chemotherapy process, the combina-
tion of anti-cancer drugs used often causes serious side effects. 
This is mainly because the chemotherapy drugs affect healthy 
body cells as well cancer cells. Many organs, such as the kid-
neys, liver, testicles, ovaries, and lungs, can be damaged by these 
drugs. In an effort to reduce the number of side effects, the 
chemotherapy is given in cycles, and each round of treatment is 
followed by a rest period, so the body has time to recover. Some 
of the main side effects of chemotherapy are loss of hair and 
appetite, vomiting and nausea, constipation, and mouth sores. 
Chemo drugs also affect the normal cells in bone marrow, which 
can lower blood cell counts. This leads to an increased risk of 
infections, due to low white blood cell counts, easy bleeding 
and bruising from low platelet counts, and constant fatigue and 
shortness of breath, as patients do not have enough red blood 
cells (hemoglobin) to carry the oxygen needed in their bodies 
(Pui, et. al., 2008).
As with most treatments, steps can be taken to reduce the 
toll these side effects can have on the patients. Drugs, such as 
Ondansetron (Zofran) can be given to decrease nausea and 
vomiting.  Transfusions or drugs can be administered to raise 
a platelet or red blood cell count, and antibiotics are given 
at the earliest sign of a developing infection. Even tumor lysis 
syndrome can be prevented. This potentially life-threatening 
side effect of chemo is usually seen in the induction phase of 
treatment. As the leukemia cells are killed by the chemo drugs, 
they break open, releasing their contents into the bloodstream. 
These components can overwhelm the kidneys because they 
are unable to filter out and remove all these substances from 
the blood at once, and the excess amounts of certain minerals 
can affect the heart and nervous system. Administering certain 
drugs and extra fluids during treatment can help the body elim-
inate these substances (Goldman, et. al., 2001). Patients need to 
be carefully monitored while being treated with cancer drugs to 
reduce the risk of these side effects as much as possible. 
High-energy radiation used to kill cancer cells is another 
therapy used to treat ALL. Most often, external beam radiation 
therapy is used, in which a machine delivers a beam of radiation 
to a specific part of the body at a certain angle. Although radia-
tion is not used as the main treatment for ALL, it is used in cer-
tain situations, such as preventing or treating leukemia that has 
spread to the brain, (though lately, radiation has been omitted 
from treatment plans) spinal fluid, and testicles. Before a bone 
marrow or peripheral blood stem cell transplant takes place, 
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the whole body often needs radiation. Rarely, radiation can help 
shrink a tumor if it is causing breathing problems by pressing on 
the trachea, although chemotherapy is often used instead, as it 
normally achieves the same effect more rapidly (Cherlow, et. al., 
1993). The side effects of radiation therapy depend on the loca-
tion at which the radiation beam was targeted. The treated area 
can appear sunburned and undergo hair loss.  Radiation to the 
abdomen can sometimes cause nausea, vomiting, or diarrhea. 
Effects of radiation that targets large parts of the body may in-
clude fatigue, shortness of breath, and an increased risk of infec-
tion due to lower blood cell counts (Pearce, et. al., 2012). 
One of the most serious, but not very common side effects of 
ALL chemotherapy and radiation therapy is an increased risk of 
getting another neoplasm, a new and abnormal growth of tissue 
in some part of the body that can become cancerous later on. 
Although effective treatments for ALL now result in five-year 
survival rates above 70%, the treatments used are ironically 
carcinogenic. Studies show that there is a substantial chance 
of secondary neoplasms among patients treated for ALL with 
chemotherapy and radiation. Children five years old and under, 
as well as patients who received radiation as a form of therapy, 
are at a higher risk for second tumors arising in their central 
nervous system, as well as patients who received radiation as a 
form of therapy. (Neglia, et. al., 1991).
Allogenic hematopoietic stem-cell transplantation, the trans-
plantation of multipotent hematopoietic stem cells, is the most 
intensive form of treatment for ALL. This stem cell transplan-
tation seems to benefit several types of high risk ALL patients, 
such as patients with poor initial responses to treatments, 
patients who have relapsed, and those with Philadelphia chro-
mosome-positive disease (Pui, et. al., 2008). The Philadelphia 
chromosome (Ph) is the most frequent cytogenetic abnormal-
ity in adult ALL. Most patients with Ph+ ALL cannot be treated 
with chemotherapy alone, as chemotherapy can only induce a 
complete remission for a few months until most patients expe-
rience a relapse. The five-year survival rates for those who have 
Ph+ ALL and were treated with chemotherapy alone are less 
than 10%. However, those who underwent allogenic stem cell 
transplantation during early remission have a 35-65% chance of 
long-term survival (Lee, et. al., 2005). Bone marrow transplants 
(BMT) are sometimes needed as well for patients with underly-
ing malignancies or genetic disorders (Slavin, wt. al., 1998).
Targeted cancer drugs are also being used as a treatment for 
ALL. Cancer cells are cells that undergo changes to their genes. 
These changes cause the cancer cells to grow faster and work 
differently from others. Targeted cancer drugs use these differ-
ences in cell genes to differentiate them from other normal cells 
and target the specific gene changes. The main targeted cancer 
drugs used for ALL are tyrosine kinase inhibitors (TKIs). They 
block tyrosine kinases, chemicals that cells use to signal to each 
other. The main side effects of targeted cancer drugs, specifically 
TKIs, are fatigue, a sore mouth, rashes or reddening of the skin, 
and loss of appetite (Pui, et. al., 2008).
Success Rates
Chemotherapy affects children and adults with ALL differently. 
Children that undergo chemotherapy treatment have a much 
greater chance of survival than adults, yet only 80 – 85% of 
children can be cured. A large chemotherapy trial comprised 
of children up to eighteen years old was conducted on 1,114 
patients. Of those patients, only 998 became protocol patients, 
and were divided into three groups; a standard risk group, those 
without central nervous system (CNS) disease, a risk group, 
those with CNS disease, and an experimental group. They all re-
ceived induction therapy and some variation of continued che-
motherapy, including cranial irradiation as needed. Additionally, 
an intensive reinduction therapy was added for patients in the 
standard risk group who had increased risk of failure during the 
trial. The event-free survival for the 110 patients who did not 
receive reinduction therapy was almost 30% lower than those 
with reinduction therapy. In this trial, a complete remission was 
measured by several parameters: the absence of leukemic cells 
in the blood and CSF, fewer than 5% lymphoblasts in marrow, 
and no evidence of localized disease. Relapse was defined as 
reappearance of lymphoblasts or localized leukemia infiltrates 
at any site (Reiter, et. al., 1994).    
Figure 1 presents results of this trial. Of the 998 patients, 985 
(98.7%) entered complete remission. Thirteen patients did not 
enter remission; seven had resistant leukemia, one died of renal 
failure, and five died an early toxic death. At the 5.0-year (range 
3.4 - 6.9 years) median follow up, 233 patients experienced a 
relapse (23.3%). Thirteen more patients died while in complete, 
continuous remission and three patients developed a second 
malignancy. There were 734 patients (73.5%) still in their first 
continuous complete remission. 
The six-year, event-free survival estimate was for 888 pa-
tients. The 110 patients who did not receive reinduction were 
excluded from this estimate. Of all three branches together, the 
estimate was 74% ± 2%. Detailed analysis showed that male pa-
tients had higher white blood counts (WBC), were six years 
old or greater, or had T-ALL, had a better outcome than others. 
For example, 69% ± 5% of T-ALL patients with WBC ≥ 20,000/
μL had event-free survival at six years.  This is a comparatively 
larger number than 58% ± 3% for the complementary group of 
patients with an immunophenotype other than T-cell ALL. These 
other immunophenotypes had no predictive strength for treat-
ment outcome (Reiter, et. al., 1994).
There was a trial for 525 patients under 19 with a first-time 
relapse of T-cell or B-cell ALL. The patients were treated with 
intensified, short course multi drug chemotherapy. A major aim 
of this study was to improve outcomes through a third inten-
sive chemotherapy course (R3) containing HD cytarabine and 
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etoposide. Results showed that 440 patients (84%) achieved a 
second complete remission, 25 patients (5%) died during in-
duction, and 60 patients (11%) did not respond to treatment. 
Thirty-one patients (6%) died in the second complete remis-
sion as a result of treatment-related adverse effects. Of those 
patients who achieved second complete remission, 246 patients 
(56%) suffered subsequent relapse, and six patients (1%) expe-
rienced a secondary malignant neoplasm. At a median follow-up 
of twelve years, 153 (29%) of 525 patients remained in com-
plete continuous remission. The study concluded that neither 
R3 nor adaptation of chemotherapy intensity was capable of 
improving event-free survival or of overcoming prognostic fac-
tors. Therefore, induction regimens need to be improved for 
high risk patients, and allogeneic stem cell transplant should be 
recommended in patients achieving second complete remission 
(Tallen, et. al., 2010). 
Adult recovery rates are not as high as children’s. ALL ac-
counts for about 15 – 20% of all adult leukemias. Although some 
of these patients enter complete remission, most of them re-
lapse and die. With chemotherapy alone, those younger than 
sixty have a 30 - 40% chance of recovery (Mohty, et. al., 2010). 
Anyone older than sixty has less than 10% chance. In many 
cases, chemotherapy is not enough and adult patients need 
other therapies, such as transplants. However, the patients still 
need to undergo chemotherapy maintenance after the induc-
tion therapy and transplant. (Goldstone, et. al., 2008).  
A study was performed on 609 adults with relapsed ALL, all of 
whom were previously treated in the Medical Research Council 
study, in which the overall survival of newly diagnosed patients 
was 38% at 5 years. By contrast, in this chemotherapy study, 
the overall survival at 5 years after relapse was 7%. Factors 
predicting a good outcome after salvage therapy were young 
age (overall survival of 12% in patients younger than 20 years 
vs overall survival of 3% in patients older than 50 years) and 
short duration of first remission. Treatment received in the first 
complete remission did not influence the outcome after relapse. 
This study concluded that adults who have an ALL relapse can-
not be rescued using currently available therapies, even if stem 
cell transplantation is available. 
Prevention of recurrence would 
be the best strategy for long-term 
survival from this disease (Fielding, 
et. al., 2007).
The most common cause of 
ALL treatment failure is relapse, 
as approximately 15 – 20% of 
children experience relapse. With 
intensive chemotherapy and trans-
plantations, 30-50% of all children 
with relapsed ALL can be cured. 
However, because relapsed ALL is 
difficult to treat, most relapsed children still die, despite the 
aggressive therapies (Locatelli, et. al., 2012). CAR T-cell therapy 
may be able to overcome the limitations of conventional thera-
pies and induce remission in patients with relapsed and refrac-
tory ALL (Maude, et. al., 2014). In one trial, thirty patients were 
selected. Twenty-five patients were aged from five to twen-
ty-two, and the other five patients between twenty-six and sixty. 
Of these patients, twenty-six had B-cell ALL in a first to fourth 
relapse, three had primary refractory B-cell ALL, and one pa-
tient had relapsed T-cell ALL. Eighteen patients had experienced 
their relapsed ALL after allogenic stem-cell transplantation. All 
the patients in this study experienced CRS. Eight patients devel-
oped severe CRS, and all required respiratory support and va-
sopressor support for hypotension. However, all neurotoxicity 
was reversible and there was no lasting damage form the CRS 
(Maude, et. al., 2014).
One month after the infusion, twenty-seven patients (90%) 
obtained complete remission. Of these patients, nineteen 
remained in remission. Fifteen patients received no further 
therapy, and five withdrew to receive other treatments. At six 
months, the event-free survival rate was 67%, and the overall 
survival rate was 78%. This is a much better rate than the <25% 
complete remission rates of the recently approved drugs (nelar-
abine, liposomal-encapsulated vincristine, and clofarabine) for 
ALL. This study showed an encouraging sustained remission of 
up to two years (Maude, et. al., 2014).      
In another trial, 53 pretreated adults received CAR T-cell 
therapy. A total of thirty-six patients (68%) received CAR T-cell 
therapy as a third or later salvage treatment, twelve had primary 
refractory disease, nineteen had undergone allogeneic hema-
topoietic stem-cell transplantation previously, and thirteen had 
received the drug blinatumomab previously. A total of sixteen 
patients had Philadelphia chromosome positive ALL, and ten of 
the sixteen patients had disease that was refractory to the drug 
ponatinib. After infusion, 26% of the patients had severe CRS. 
Complete remission was defined as less than 5% bone marrow 
blasts, the absence of circulating blasts, and no extramedullary 
sites of disease regardless of cell-count recovery. Relapsed 
998 Patients
998 Patients:Complete
remission
(98.7%)
*16 Patients died
13 in complete continuous
remission
3 from second malignancy
*233 Patients Relapsed
(23.3%)
*734 Patients(73.5%) were
still in their first continuous 
remission
13 Patients:
7 Resistant Leukemia
6 Died
*5.0 year (range 3.4 - 6.9) median follow upFigure 1: Breakdown of patients in the trial
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disease was defined as the reappearance of blasts in blood or 
bone marrow or in an extramedullary site after a complete 
remission. One patient died from multiorgan failure and severe 
CRS on day five, and complete remission was observed in 83% 
of the patients. At a median follow-up of twenty-nine months 
(range one to sixty-five), the median event-free survival was 6.1 
months, and the overall survival was 12.9 months. Patients with 
a low disease burden (<5% bone marrow blasts) before treat-
ment had distinctly enhanced remission duration and survival, 
with a median event-free survival of 10.6 months and a median 
overall survival of 20.1 months. Patients with a higher burden 
of disease (≥5% bone marrow blasts or extramedullary disease) 
had a greater incidence of the cytokine release syndrome and 
neurotoxic events and shorter long-term survival than did pa-
tients with a low disease burden. This is a better outcome than 
the three to nine months of median overall survival seen from 
chemotherapy (Park, et. al., 2018). 
Of the 44 patients who had a complete remission after the 
infusion of CAR T-cells, 26 did not undergo further therapy, 
including nine who were alive and seventeen who had a re-
lapse or died. One patient received alternative treatment for 
minimal residual disease–positive disease, and seventeen pa-
tients progressed to transplantation. The median time from the 
CAR T-cell infusion to transplantation was 74 days (range, 44 
to 312). Of the seventeen patients who underwent allogeneic 
transplantation after the CAR T-cell infusion, five patients were 
alive and had a complete remission, six had a relapse, and six 
died from transplant-related toxic effects. This study showed 
that CAR T-cell therapy had favorable long-term remission rates 
in a population of patients with low disease burden, who had 
significantly longer event-free survival and overall survival with 
markedly lower incidences of toxic effects than did those with 
a high disease burden (Park, et. al., 2018).
In another trial, 20 patients (aged 1-30 years, including eight 
patients who underwent allogenic stem-cell transplantation) 
with relapsed or refractory ALL were infused with CAR T-cells. 
CRS was recorded in 16 patients, and all toxicities associated 
with the therapy were reversable. Complete remission was ob-
served in 70% of the patients. Many of the patients in the trial 
underwent further stem cell transplantation therapy, which led 
to the conclusion that CAR T-cell therapy is an effective bridge 
to stem cell transplantation for patients with chemo refractory 
B-ALL. Because most patients who entered remission eventually 
underwent stem cell transplantation, this study was not able to 
assess the durability of response to the CAR T-cells, yet it was 
associated with a favorable long-term survival. Additionally, this 
study showed that CAR T-cells mediate a complete remission 
in refractory ALL that is substantially higher than the 8-20% 
reported with clofarabine, a drug that was approved in 2004 for 
refractory pediatric ALL (Lee, et. al., 2014). 
Conclusion
CAR T-cell therapy is currently being used as a treatment for 
patients who have already been treated with other therapies 
and relapsed. This makes the effectiveness of the therapy diffi-
cult to gauge, as CAR T-cell therapy trial outcomes cannot be 
compared to first time treatment data of other therapies such 
as chemotherapy. Nevertheless, the trials have shown that the 
toxicities from CAR T-cell therapy are manageable and are no 
longer a big concern. The trials also show that although it does 
not have perfect results, CAR T-cell therapy is far more suc-
cessful in treating relapsed ALL than other therapies have been, 
as the complete remission rates and longer survival rates are 
higher for relapsed ALL than any other treatment. Some studies 
indicated that many patients may have needed additional stem 
cell transplants and other therapies after undergoing CAR T-cell 
therapy, so it cannot always be used as a lone therapy. However, 
some patients did achieve event-free remission from only CAR 
T-cell therapy. There were no attempts in proving that CAR 
T-cell therapy should not be done, making this therapy a great 
treatment option for ALL, especially relapsed ALL. 
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